B · Normal
[Merck’s third-quarter revenue increased 5% to US$18.1 billion, raising full-year performance guidance] October 29th, Merck’s third-quarter global revenue was US$18.085 billion, a year-on-year increase of 5%; net profit was US$5.065 billion, a year-on-year decrease of 12%; adjusted earnings per share was US$2.49, compared with US$2.58 in the same period last year. Sales of core products Keytruda and Keytruda Qlex were US$8.601 billion, a year-on-year increase of 6%; sales of pulmonary hypertension drug Winrevair were US$694 million, a year-on-year increase of 93%. The company raised its full-year revenue guidance to $66.8 billion to $67.3 billion, and raised its full-year adjusted earnings per share guidance to $2.77 to $2.82.
Comments